Skip to Main Content

Paper Details

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
Br J Cancer
39
2015
(131)I-MIBG, (131)I-metaiodobenzylguanidine, MIBG, Myelosuppression, Patients, UGT1A1, UGT1A1*28, advanced neuroblastoma, cefixime, diarrhoea, irinotecan, neuroblastoma, patients, peripheral blood stem cells, thrombocytopenia, vincristine
Author NameAffiliation
Steven G DuBoisUCSF School of Medicine, UCSF Benioff Children's Hospital
Yael P MosseUniversity of Pennsylvania School of Medicine and Children's Hospital of Philadelphia
  • 1 - 2

Datasets

Release 1.2